Capivasertib
FDA-approved product (tablet, oral), marketed as Truqap.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast neoplasm
- Cancer
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other protein kinase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Capivasertib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587 · start 2018-10-11
Registered record
- Registry ID
- NCT03616587
- Conditions
- ER+ HER2- Advanced Breast Cancer
- Interventions
- AZD9833; AZD9833; AZD9833 with palbociclib; AZD9833 with palbociclib; AZD9833 with everolimus; AZD9833 with everolimus; AZD9833 with abemaciclib; AZD9833 with abemaciclib; AZD9833 with capivasertib; AZD9833 with capivasertib; AZD9833 with ribociclib; AZD9833 with ribociclib; AZD9833 with anastrozole; AZD9833 with anastrozole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2018-10-11
- Completion
- 2027-06-24
- Enrolment
- 396
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionER+ HER2- Advanced Breast CancerInterventionAZD9833; AZD9833; AZD9833 with palbociclib; AZD9833 with palbociclib +10 morePhasePhase 1Registry statusActive not recruitingTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826 · start 2018-09-27
Registered record
- Registry ID
- NCT03660826
- Conditions
- Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Capivasertib; Cediranib Maleate; Computed Tomography; Durvalumab; Echocardiography Test; Multigated Acquisition Scan; Olaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2018-09-27
- Completion
- 2027-07-01
- Enrolment
- 288
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma +2 moreInterventionBiospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Capivasertib +6 morePhasePhase 2Registry statusActive not recruitingAZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
NCT03310541 · start 2017-10-11
Registered record
- Registry ID
- NCT03310541
- Conditions
- Breast Cancer; Prostate Cancer; Advanced Solid Tumors
- Interventions
- AZD5363; Enzalutamide; Fulvestrant
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-10-11
- Completion
- 2023-05-03
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Prostate Cancer; Advanced Solid TumorsInterventionAZD5363; Enzalutamide; FulvestrantPhasePhase 1Registry statusCompletedThe UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
NCT03182634 · start 2016-12-15
Registered record
- Registry ID
- NCT03182634
- Conditions
- Advanced Breast Cancer
- Interventions
- Fulvestrant; Neratinib; AZD5363; Olaparib; AZD6738
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2016-12-15
- Completion
- 2023-11
- Enrolment
- 1,150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Breast CancerInterventionFulvestrant; Neratinib; AZD5363; Olaparib +1 morePhasePhase 2Registry statusUnknownTesting AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
NCT04439123 · start 2016-05-31
Registered record
- Registry ID
- NCT04439123
- Conditions
- Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
- Interventions
- Capivasertib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2016-05-31
- Completion
- 2027-03-31
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma +2 moreInterventionCapivasertibPhasePhase 2Registry statusActive not recruitingOLAParib COmbinations
NCT02576444 · start 2015-11
Registered record
- Registry ID
- NCT02576444
- Conditions
- Cancer
- Interventions
- AZD2281; AZD5363; AZD1775; AZD6738
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2015-11
- Completion
- 2019-11-18
- Enrolment
- 67
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCancerInterventionAZD2281; AZD5363; AZD1775; AZD6738PhasePhase 2Registry statusTerminatedTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060 · start 2015-08-17
Registered record
- Registry ID
- NCT02465060
- Conditions
- Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
- Interventions
- Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2015-08-17
- Completion
- 2026-12-31
- Enrolment
- 6,452
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 moreInterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 morePhasePhase 2Registry statusActive not recruitingTrial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
NCT02449655 · start 2015-02-12
Registered record
- Registry ID
- NCT02449655
- Conditions
- Advanced Gastric Adenocarcinoma
- Interventions
- AZD5363; paclitaxel; AZD2014; paclitaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2015-02-12
- Completion
- 2018-07-16
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Gastric AdenocarcinomaInterventionAZD5363; paclitaxel; AZD2014; paclitaxelPhasePhase 2Registry statusTerminatedStudy of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
NCT02451956 · start 2015-01-07
Registered record
- Registry ID
- NCT02451956
- Conditions
- Advanced Gastric Cancer
- Interventions
- AZD5363; paclitaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-01-07
- Completion
- 2019-05-24
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Gastric CancerInterventionAZD5363; paclitaxelPhasePhase 2Registry statusCompletedA Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
NCT02525068 · start 2014-12
Registered record
- Registry ID
- NCT02525068
- Conditions
- Adenocarcinoma of the Prostate
- Interventions
- AZD5363; Enzalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2014-12
- Completion
- 2020-03
- Enrolment
- 136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenocarcinoma of the ProstateInterventionAZD5363; EnzalutamidePhasePhase 2Registry statusUnknownmTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
NCT02208375 · start 2014-11-11
Registered record
- Registry ID
- NCT02208375
- Conditions
- BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast Carcinoma
- Interventions
- Capivasertib; Laboratory Biomarker Analysis; Olaparib; Pharmacological Study; Vistusertib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2014-11-11
- Completion
- 2028-06-30
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative +12 moreInterventionCapivasertib; Laboratory Biomarker Analysis; Olaparib; Pharmacological Study +1 morePhasePhase 1Registry statusActive not recruitingPAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
NCT02423603 · start 2014-05-14
Registered record
- Registry ID
- NCT02423603
- Conditions
- Metastatic Breast Cancer
- Interventions
- Paclitaxel; AZD5363; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-05-14
- Completion
- 2024-06-30
- Enrolment
- 71
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Breast CancerInterventionPaclitaxel; AZD5363; PlaceboPhasePhase 2Registry statusCompletedSAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
NCT02117167 · start 2014-04-23
Registered record
- Registry ID
- NCT02117167
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Standard maintenance for squamous NSCLC; Pemetrexed; Durvalumab; savolitinib; Olaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-04-23
- Completion
- 2023-12
- Enrolment
- 999
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung Cancer MetastaticInterventionAZD2014; AZD4547; AZD5363; AZD8931 +7 morePhasePhase 2Registry statusCompletedSAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
NCT02299999 · start 2014-04-07
Registered record
- Registry ID
- NCT02299999
- Conditions
- Metastatic Breast Cancer
- Interventions
- AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Bicalutamide; Olaparib; Anthracyclines; Taxanes; cyclophosphamide; DNA intercalators; Methotrexate; vinca alkaloids; Platinum based chemotherapies; Bevacizumab; Mitomycin C; Eribulin; MEDI4736
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2014-04-07
- Completion
- 2025-12
- Enrolment
- 1,460
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Breast CancerInterventionAZD2014; AZD4547; AZD5363; AZD8931 +15 morePhasePhase 2Registry statusActive not recruitingTrial of Olaparib in Combination With AZD5363 (ComPAKT)
NCT02338622 · start 2014-03-31
Registered record
- Registry ID
- NCT02338622
- Conditions
- Advanced Cancer
- Interventions
- olaparib; AZD5363
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-03-31
- Completion
- 2017-03-21
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced CancerInterventionolaparib; AZD5363PhasePhase 1Registry statusCompleted